<DOC>
	<DOCNO>NCT01645891</DOCNO>
	<brief_summary>The purpose study evaluate safety effectiveness Continuous Diffusion Oxygen ( CDO ) therapy treatment Diabetic Foot Ulcers . The primary objective study evaluate effectiveness CDO combination standard moist wound therapy ( MWT ) wind heal compare standard MWT alone .</brief_summary>
	<brief_title>A Prospective , Randomized , Double-Blind Multicenter Study Comparing Continuous Diffusion Oxygen ( CDO ) Therapy Standard Moist Wound Therapy ( MWT ) Treatment Diabetic Foot Ulcers</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Diabetic Foot</mesh_term>
	<mesh_term>Foot Ulcer</mesh_term>
	<criteria>Subjects 3090 year age time Informed Consent Subjects type 1 type 2 Diabetes Mellitus nonhealing , fullthickness , University Texas Classification Diabetic Foot Ulcers Class IA diabetic foot ulcer Subjects ulcer duration least 4 week , great 52 week time screen Subjects index ulcer measure 1 10 cm2 area debridement ( Area = length x width ) Subjects diabetic foot ulcer ( ) malleoli Subjects demonstrate adequate arterial perfusion define either : transcutaneous oxygen measurement dorsum foot &gt; 30 mm Hg skin perfusion pressure &gt; 30 mm Hg , ankle/brachial index ( ABI ) 0.7 , document confirmation adequate arterial perfusion , Doppler waveform consistent adequate flow foot ( biphasic triphasic waveform ) screening , absolute toe pressure &gt; 30 mm Hg Subject and/or caregiver must able willing learn perform duty dress change Subjects able willing comply standardize offload regimen ( fix ankle walker ) Subjects &lt; 30 &gt; 90 year age time Informed Consent Subjects Target Ulcers duration &lt; 4 week &gt; 52 week Subjects ulcer measure less 1 cm2 great 10 cm2 area ( Area = length x width ) debridement time screen Subjects whose ulcer decrease area &gt; 30 % 1 week screen period Subjects evidence gangrene part affect limb Subjects active Charcot 's foot study limb Subjects schedule undergo vascular surgery , angioplasty thrombolysis time enrollment Subjects active infection time screen Subjects target ulcer expose tendon , ligament , muscle , bone Subjects active malignancy , exclude nonmelanoma skin cancer Subjects history malignancy study limb Subjects oral , IV antibiotic/antimicrobial agent medication use within 2 day ( 48 hour ) baseline Subjects currently receive receive radiation chemotherapy within 3 month randomization Subjects receive growth factor therapy ( e.g. , autologous plateletrich plasma gel , becaplermin , bilayered cell therapy , dermal substitute , extracellular matrix ) within two week screen Subjects pregnant time screen Subjects undergo active renal dialysis Subjects know immune insufficiency , exclude Diabetes Mellitus Subjects history peripheral vascular repair within 14 day screen Subjects current deep vein thrombosis ( DVT ) Subjects ulcer due Raynaud 's disease Subjects ulcer due acute thrombophlebitis Subjects inadequate perfusion support heal Subjects necrotic wound cover eschar slough Subjects wound fistulae deep sinus tract unknown depth Subjects receive palliative care Subjects HbA1c &gt; 12 % ( uncontrolled hyperglycemia ) Subjects whose target ulcer know etiology : malignancy , burn , collagen vascular disease , sickle cell , vasculopathy , pyoderma gangrenosum Subjects document history alcohol substance abuse within 6 month screen Subjects currently enrol participate , within 30 day screen , another investigational device , drug biological trial may interfere study result Subjects know allergy dress material , include occlusive dressing adhesive dressing</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Diabetic Foot Ulcer</keyword>
</DOC>